Evidence map›Paper›PMID 42366176›Full record

ArticleDiabetes, obesity & metabolism2026

Real-World Associations of KidneyIntelX Risk Stratification With Guideline-Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease.

David Lam, Barry I Freedman, Joji Tokita, Fergus Fleming, Mayte Suarez-Farinas, Benjamin Bagwell, Julienne Kirk, Hazel Tapp, Lindsay Shade, Aida Vega and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

David LamDivision of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID https://orcid.org/0000-0002-0943-0870
Barry I FreedmanDepartment of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Joji TokitaBarbara T Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Fergus FlemingRenalytix AI, PLC, New York, New York, USA.
Mayte Suarez-FarinasDivision of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Benjamin BagwellDepartment of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Julienne KirkDepartment of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Hazel TappDepartment of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Lindsay ShadeDepartment of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Aida VegaDivision of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Stephanie WangDivision of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Catherine SinfieldDivision of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Steven G CocaBarbara T Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID https://orcid.org/0000-0002-0928-9168
Girish N NadkarniBarbara T Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID https://orcid.org/0000-0001-6319-4314
Michael J DonovanRenalytix AI, PLC, New York, New York, USA.

Funding

Renalytix
6 · The paper itself

Abstract

backgroundKidneyIntelX is a prognostic blood test for the progression of diabetic kidney disease (DKD) within 5 years. Long-term utility is important. MATERIALS AND

methodsAdults with type 2 diabetes (T2D) and CKD (G1-G3b) from two medical centres were assessed for the following: (1) baseline KidneyIntelX risk levels and their association with GDMT usage; (2) changes in temporal kidney and metabolic trajectories after testing; (3) probability for a kidney composite outcome of sustained eGFR decline of 40% or kidney failure by baseline KidneyIntelX risk strata; and (4) risk at 12-month for repeat-tested participants.

results2470 patients with T2D and CKD (median baseline eGFR 63 mL/min/1.73 m

conclusionsKidneyIntelX was associated with targeted GDMT usage with favourable changes in kidney and metabolic clinical measures and risk trajectories, with lower risk linked to therapy initiation and reduction in biomarkers.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesAgedBiomarkersDisease ProgressionFemaleGlomerular Filtration RateHumansHypoglycemic AgentsKidneyMaleMiddle AgedPractice Guidelines as TopicPrognosisRisk AssessmentSodium-Glucose Transporter 2 InhibitorsBiomarkersHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitorscohort studydiabetic nephropathyGLP‐1real‐world evidenceSGLT2 inhibitor

Identifiers

PMID42366176
PMCPMC13448964

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.